Tech Center 1600 • Art Units: 1644
This examiner grants 67% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18546081 | MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1 | Non-Final OA | The Regents of the University of California |
| 18274069 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH AVB8 INTEGRIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18283196 | MATERIALS AND METHODS FOR TREATING CANCER | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18038185 | HER2 TARGETING AGENT | Final Rejection | TOHOKU UNIVERSITY |
| 18094176 | Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc |
| 18249241 | COMPOSITIONS AND METHODS FOR MUC18 TARGETING | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18254255 | HUMANIZED ANTIBODIES AND FRAGMENTS THEREOF BINDING TO CARBOHYDRATE ANTIGENS AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18551553 | Pharmaceutical Combinations for Treating Cancer | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18124717 | SOLUBLE CD28 LEVELS AFTER IMMUNOTHERAPY | Final Rejection | BIOND BIOLOGICS LTD. |
| 17914855 | IMMUNE ACTIVATING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18190199 | PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | BGI SHENZHEN |
| 18019871 | Combined Preparation | Final Rejection | MEDRx Co., Ltd. |
| 18261376 | ANTI-CD38 ANTIBODIES AND THEIR USES | Non-Final OA | MORPHOSYS AG |
| 17586067 | METHODS OF USE FOR CAR T CELLS | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18253493 | ANTI-CD25 ANTIBODIES | Non-Final OA | UNIVERSITE PARIS EST CRETEIL VAL DE MARNE |
| 17594271 | MULTI-VALENT IMMUNOTHERAPY COMPOSITION AND METHODS OF USE FOR TREATING WT1-POSITIVE CANCERS | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 17251425 | METHODS FOR PREDICTING RESPONSIVENESS OF LUNG CANCER PATIENTS TO HER2-TARGETING THERAPIES | Final Rejection | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18137279 | [6R]-MTHF IN B6 ENHANCED 5-FU BASED CHEMOTHERAPY OF CARCINOMA | Non-Final OA | Isofol Medical AB |
| 17909358 | GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF | Non-Final OA | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
| 18028698 | FIBRONECTIN EXTRA DOMAIN B (EDB) -SPECIFIC CAR-T FOR CANCER | Non-Final OA | JIANGSU CELL TECH MEDICAL RESEARCH INSTITUTE CO., LTD. |
| 18245222 | COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER | Non-Final OA | Jaqueline WILLEMANN ROGERIO |
| 17997025 | ANTIBODY BINDING WITH SPECIFIC EPITOPE IN HUMAN IL-4R ALPHA AND APPLICATIONS OF ANTIBODY | Non-Final OA | CONNECT BIOPHARMA HONGKONG LIMITED |
| 17996022 | Anti-IL13R-alpha2 Antibodies, Antigen-Binding Fragments and Uses Thereof | Non-Final OA | ELICERA THERAPEUTICS AB |
| 17171426 | TARGETED HUMAN-INTERFERON FUSION PROTEINS | Final Rejection | Universitat Osnabruck |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy